Enliven Therapeutics, Inc. Common Stock
Symbol: ELVN (NASDAQ)
0.00
▼ (-100.00%) -19.220
Company Description:
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $19.22
- Yesterday High: $20.235
- Yesterday Low: $19.035
- Yesterday Volume: 369.67K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: Enliven Therapeutics, Inc. Common Stock
- Website: https://www.enliventherapeutics.com
- Listed Date: 2023-02-24
- Location: BOULDER, CO
- Market Status: Active
- CIK Number: 0001672619
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.14B
- Round Lot: 100
- Outstanding Shares: 59.24M
- Asset Type: CS
RECENT FILINGS FOR ELVN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 4 | View |
| 2025-09-08 | 144 | View |
| 2025-08-29 | 4 | View |
| 2025-08-27 | 144 | View |
| 2025-08-21 | 4/A | View |
| 2025-08-21 | 4 | View |
| 2025-08-20 | 4 | View |
| 2025-08-19 | 144 | View |
| 2025-08-18 | 144 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-08-13 | S-3ASR | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-08-11 | 4 | View |
| 2025-08-07 | 144 | View |
| 2025-07-30 | 4 | View |
| 2025-07-28 | 144 | View |
| 2025-07-23 | 4 | View |
Latest News on ELVN